FDA
-
-
-
-
-
-
-
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
-
-
-
-
-
-
-
Heron Therapeutics (HRTX) Announces US District Court Upheld Validity of CINVANTI Patents
-
-
-
-
-
-
-
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
-
-
-
-
-
-
-
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
-
-
-
-
-
-
-
Heron Therapeutics Announces Commercial Leadership Changes
-
-
-
-
-
-
-
Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital
-
-
-
-
-
-
-
Heron Therapeutics (HRTX) Announces 16.13M Share Private Placement at $3.10/sh
-
329,204 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

